Particularly, miR25, miR221, and miR222 were reported as able to directly target CDKN1C RNA in gastric cancer [142], hepatocellular carcinoma (HCC), and human T-cell lymphoblastic lymphomas [143], and miR-92b has been reported as responsible for p57 downregulation in HCC tissues and cell lines, enhancing tumor radio-resistance to ionization radiation (IR)-based radiotherapy [144]. The gene discussed is CDKN1C; the disease is neoplasm.